Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

SUZHOU, China and PALO ALTO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming conferences:

Goldman Sachs Asia Pacific Healthcare Forum 2021

One-on-one and small group meetings (virtual): November 15-17, 2021

For more information, please contact your Goldman Sachs representative.

8^th BioCentury-BayHelix China Healthcare Summit

In-person one-on-one and small group meetings (Shanghai, China): November 17, 2021

Panel – China Biotech CEO Blue Ribbon Roundtable: November 17, 2021, 14:30-15:15pm CST

For more information, please contact your Biocentury representative.

Jefferies London Healthcare Conference

One-on-one and small group meetings (virtual): November 18-19, 2021

Fireside Chat: available on-demand beginning on Thursday, November 18, 3:00am ET

Webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

The replay of the fireside chat can be accessed through the “News and Events” section of the Gracell Investor website.

For more information, please contact your Jefferies representative.

20^th Morgan Stanley Annual Asia Pacific Summit

One-on-one and small group meetings (virtual): November 18-19, 2021

For more information, please contact your Morgan Stanley representative.

About Gracell

Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com

Follow @GracellBio on LinkedIn

Media contact

Marvin Tang

marvin.tang@gracellbio.com

Investor contact

Gracie Tong

gracie.tong@gracellbio.com